NASDAQ:ARWRArrowhead Pharmaceuticals Stock Price, Forecast & News

Arrowhead Pharmaceuticals' stock was trading at $28.56 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARWR stock has increased by 15.9% and is now trading at $33.09. View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) posted its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.09. The biotechnology company earned $23.53 million during the quarter, compared to analysts' expectations of $21.90 million. Arrowhead Pharmaceuticals had a net margin of 6.86% and a return on equity of 2.61%. View Arrowhead Pharmaceuticals' earnings history.

10 Wall Street analysts have issued 12-month target prices for Arrowhead Pharmaceuticals' stock. Their forecasts range from $29.00 to $81.00. On average, they anticipate Arrowhead Pharmaceuticals' share price to reach $62.00 in the next twelve months. This suggests a possible upside of 87.4% from the stock's current price. View analysts' price targets for Arrowhead Pharmaceuticals.

Media stories about ARWR stock have trended somewhat positive on Friday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arrowhead Pharmaceuticals earned a coverage optimism score of 0.7 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutArrowhead Pharmaceuticals.

Some companies that are related to Arrowhead Pharmaceuticals include GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Beigene (BGNE), Sarepta Therapeutics (SRPT), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Mylan (MYL), Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Ascendis Pharma A/S (ASND) and Bausch Health Companies (BHC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Micron Technology (MU), Bank of America (BAC), Alliance Resource Partners (ARLP), Sasol (SSL), Sarepta Therapeutics (SRPT) and Advanced Micro Devices (AMD).

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Arrowhead Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.23%), State Street Corp (4.22%), Invesco Ltd. (3.11%), First Manhattan Co. (1.59%), Geode Capital Management LLC (1.49%) and Fiera Capital Corp (1.31%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View institutional ownership trends for Arrowhead Pharmaceuticals.

ARWR stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Deutsche Bank AG, UBS Group AG, JPMorgan Chase & Co., Principal Financial Group Inc., Invesco Ltd., First Trust Advisors LP, and Federated Hermes Inc.. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, and Patrick O'brien. View insider buying and selling activity for Arrowhead Pharmaceuticals.

ARWR stock was acquired by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Nuveen Asset Management LLC, AQR Capital Management LLC, State Street Corp, Prosight Management LP, and Quantitative Investment Management LLC. View insider buying and selling activity for Arrowhead Pharmaceuticals.

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARWR stock can currently be purchased for approximately $33.09.

Arrowhead Pharmaceuticals has a market capitalization of $3.37 billion and generates $168.80 million in revenue each year. The biotechnology company earns $67.97 million in net income (profit) each year or $0.69 on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe.

The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com.

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]